In Vivo Immune Cell Programming with mRNA-LNP Therapeutics

• In vivo CAR mRNA-LNP platform selectively generates CAR-T, CAR-NK, and myeloid CAR cells directly in patients
• Clinically validated with data from 50+ patients and demonstrated tolerable repeat dosing
• Best-in-class in vivo CARs across oncology and autoimmunity, including first clinical responses with in vivo CARs outside blood cancers

Speakers:

Daniel Getts

Chief Executive Officer & Co-Founder

CREATE Medicines